Cadence Molecular Sciences (CDNS) announced that Pfizer (PFE) has signed an agreement to extend and expand access to Cadence products and programming toolkits for advanced molecular design. Cadence Molecular Sciences’ physics-and AI-based modeling and cheminformatics computational software is an enabler of early-stage drug discovery innovation. The software is used by major pharmaceutical and biotech companies worldwide to help accelerate and advance therapeutic research.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CDNS:
- ASML, TSM, CDNS: Missed the Chip Stock Rip? Analysts Still Love These 3 Stocks
- Cadence Design price target raised to $262 from $257 at Baird
- Cadence Design falls 5% to $229.03 after Q3 results, below-consensus Q4 guidance
- Cadence Design sees FY23 adjusted EPS $5.07-$5.13, consensus $5.09
- Cadence Design sees Q4 adjusted EPS $1.30-$1.36, consensus $1.37